HALO Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Torley Helen 2 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $107.24 | $2.1M | 772,288 −2.5% of holding | |
| Torley Helen 2 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $107.17 | $2.1M | 773,192 −2.5% of holding | |
| Torley Helen 3 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $107.43 | $2.1M | 774,476 −2.5% of holding | |
| Torley Helen 3 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $107.00 | $2.1M | 780,580 −2.5% of holding | |
| Torley Helen 3 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $104.18 | $2.1M | 782,077 −2.5% of holding | |
| Torley Helen 5 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $102.60 | $2.1M | 786,880 −2.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.